SequelSEC

Lantern Pharma Inc. LTRN

Pharmaceutical Preparations · CIK 0001763950 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$17.98M
Fiscal year ended 2025-12-31
Free cash flow
-$15.68M
Fiscal year ended 2025-12-31

Lantern Pharma Inc. (LTRN) reported net income of -$17.12M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Lantern Pharma Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Lantern Pharma Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$17.98M-$22.22M-$17.88M-$14.43M-$12.59MUnavailableUnavailable
Net income-$17.12M-$20.78M-$15.96M-$14.26M-$12.36M-$5.91M-$2.43M
Research & development$11.51M$16.13M$11.89M$8.60M$7.57M$2.24MUnavailable
Weighted-average diluted sharesshares 10.90Mshares 10.76Mshares 10.84Mshares 10.85MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.57$-1.93$-1.47$-1.31UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.46M$6.09M$5.98M$5.83M$5.02M$3.66M$1.48M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Lantern Pharma Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$4.42M$7.51M$21.94M$37.20M$51.52M$19.23M$1.23M
Total assets$11.04M$25.57M$43.65M$58.84M$73.95M$20.36M$1.43M
Current assets$10.80M$25.25M$43.34M$58.72M$72.72M$20.24M$1.23M
Total liabilities$4.50M$4.38M$2.74M$2.80M$2.38M$660.84K$489.29K
Current liabilities$4.50M$4.33M$2.68M$2.80M$2.33M$552.34K$489.29K
Total equity incl. NCI$6.53M$21.19M$40.91M$56.04M$71.57M$19.70M$943.28K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Lantern Pharma Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$15.68M-$17.81M-$14.35M-$12.77M-$10.59M-$5.65M-$2.13M
Capital expenditures$1.72K$12.60K$18.73K$27.84K$15.50KUnavailableUnavailable
Investing cash flow$11.06M$3.37M-$930.21K$179.27K-$19.53M-$16.14K-$5.72K
Financing cash flow$1.50M$66.71K-$500.00K-$2.18M$63.42M$23.66M$2.92M
Net change in cash-$3.09M-$14.43M-$15.81M-$14.78M$33.30M$18.00M$786.87K
Stock-based compensation$651.00K$652.00K$1.02M$1.19M$961.54KUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$500.00K$2.48M$939.67KUnavailableUnavailable
Depreciation & amortization$17.28K$17.28K$14.62K$10.08K$6.76K$3.39K$1.63K

Derived

Lantern Pharma Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$15.68M-$17.83M-$14.37M-$12.80M-$10.61MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.40x5.83x16.18x20.99x31.26x36.64x2.52x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LTRN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.